• Menu
  • Skip to right header navigation
  • Skip to primary navigation
  • Skip to content

DesignCaffeine, Inc.

Design That Works.

  • About
    • About Greg Nudelman
    • Clients
  • Speaking & Workshops
    • UX of AI Keynote/Workshop
    • Mobile Lean UX Academy
  • 4 Books
  • Articles
  • Contact
  • About
    • About Greg Nudelman
    • Clients
  • Speaking & Workshops
    • UX of AI Keynote/Workshop
    • Mobile Lean UX Academy
  • 4 Books
  • Articles
  • Contact
  • DesignOps
  • Artificial Intelligence
  • IoT & Analytics
  • Lean UX
  • Mobile
  • Search
  • Design Strategy
  • DesignOps
  • Artificial Intelligence
  • IoT & Analytics
  • Lean UX
  • Mobile
  • Search
  • Design Strategy

US Patent #6180615: Propargyl Phenyl Ether A2A Receptor Agonists

Key CV Therapeutics/Gilead patent for A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.

Jan 20th, 2010 //  by Greg Nudelman

2-adenosine propargyl phenyl ether compositions having the following formula: ##STR1## and methods for using the compositions as A.sub.2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.

Granted by the US Patent Office June 22, 1999 ⇒

Category: InventionsTag: Biochemistry, Medicinal Chemistry, Patent, Pharmaceutical

Previous Post: « US Patent #6677336: Substituted Piperazine Compounds
Next Post: US Patent #6677343: Substituted Piperazine Compounds »

Copyright © 2023 DesignCaffeine, Inc. · All Rights Reserved · Powered by Mai Theme